Compare · ACLS vs TMO
ACLS vs TMO
Side-by-side comparison of Axcelis Technologies Inc. (ACLS) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- ACLS operates in Technology, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $183.60B, about 39.7x ACLS ($4.62B).
- ACLS has been more active in the news (34 items in the past 4 weeks vs 17 for TMO).
- TMO has more recent analyst coverage (25 ratings vs 17 for ACLS).
- Company
- Axcelis Technologies Inc.
- Thermo Fisher Scientific Inc
- Price
- $150.50+0.07%
- $493.55+0.20%
- Market cap
- $4.62B
- $183.60B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2000
- News (4w)
- 34
- 17
- Recent ratings
- 17
- 25
Axcelis Technologies Inc.
Axcelis Technologies, Inc. designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips in the United States, Europe, and Asia. The company offers high energy, high current, and medium current implanters for various application requirements. It also provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. It sells its equipment and services to semiconductor chip manufacturers through its direct sales force. The company was founded in 1978 and is headquartered in Beverly, Massachusetts.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest ACLS
- VP Corporate Controller Sutton Todd sold $319,980 worth of shares (2,000 units at $159.99), decreasing direct ownership by 24% to 6,360 units (SEC Form 4)
- SEC Form SD filed by Axcelis Technologies Inc.
- Director St Dennis Thomas sold $139,833 worth of shares (900 units at $155.37), decreasing direct ownership by 5% to 17,695 units (SEC Form 4)
- EVP, General Counsel and Sec'y Evans Eileen sold $143,998 worth of shares (926 units at $155.51), decreasing direct ownership by 3% to 31,295 units (SEC Form 4)
- EVP, Research, Dev. & Eng. Blumenstock Gerald M sold $177,285 worth of shares (1,161 units at $152.70), decreasing direct ownership by 5% to 20,493 units (SEC Form 4)
- EVP Global Customer Operations Tatnall Christopher sold $174,608 worth of shares (1,166 units at $149.75), decreasing direct ownership by 4% to 27,627 units (SEC Form 4)
- Director Quirk Jeanne sold $250,854 worth of shares (1,789 units at $140.22), decreasing direct ownership by 14% to 11,400 units (SEC Form 4)
- Director Graves Gregory B sold $456,697 worth of shares (3,225 units at $141.61), decreasing direct ownership by 37% to 5,473 units (SEC Form 4)
- Director Kurtzweil John T sold $485,771 worth of shares (3,500 units at $138.79), decreasing direct ownership by 10% to 32,990 units (SEC Form 4)
- PRESIDENT AND CEO Low Russell covered exercise/tax liability with 711 shares, decreasing direct ownership by 0.46% to 154,900 units (SEC Form 4) (withholding obligation)
Latest TMO
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)
- Director Lynch Karen S was granted 499 shares, increasing direct ownership by 76% to 1,159 units (SEC Form 4)
- Director Keith R. Alexandra was granted 499 shares, increasing direct ownership by 24% to 2,602 units (SEC Form 4)
- Director Johnson Jennifer M was granted 499 shares, increasing direct ownership by 55% to 1,403 units (SEC Form 4)
- Director Jacks Tyler was granted 499 shares, increasing direct ownership by 6% to 9,462 units (SEC Form 4)